Inhaled Interferon α2b for the Treatment of Coronavirus Disease 19 (COVID-19)

Coronavirus Disease 2019 Clinical Trial

— IN2COVID  

Official title:

A Phase I/II Randomized, Double-blind, Placebo-controlled Study of Inhaled Interferon α2b for the Treatment of Coronavirus Disease 19 (COVID-19)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04988217
• Other study ID #: 210224003
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: September 15, 2021
• Est. completion date: July 28, 2022

Study information

• Verified date: April 2022
• Source: Pontificia Universidad Catolica de Chile
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The IN2COVID Study is a 2-staged phase I/II double-blind, randomized, placebo-controlled trial to evaluate the efficacy and safety of AP-003 (Interferon α2b) when administered via inhalation twice daily for 10 days. Participants will have a final visit at Day 11. A lead-in phase 1 substudy will be performed with at least 18 healthy adult male subjects to assess safety and tolerability of inhaled AP-003 compared to placebo for 10 days. Two cohorts of 9 subjects will be randomly assigned to receive two doses of inhaled AP-003 or placebo with an allocation ratio of 2:1. The first cohort will assess a dose of 2.5 MIU of inhaled AP-003. If no adverse events are observed, the second cohort will be conducted using a dose of 5 MIU of inhaled AP-003. Maximum tolerated dose will be determined in this phase 1 substudy. After the completion of phase 1, the study will continue with a phase 2 treatment RCT in patients with COVID-19. In this phase, 150 adults with mild or moderate COVID-19 demonstrated by SARS-CoV-2 positive polymerase chain reaction (PCR) ≤ 5 days at enrollment will be randomized 1:1 (75 in each arm) to receive nebulized AP-003 or identical placebo twice daily during 10 days.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 173
• Est. completion date: July 28, 2022
• Est. primary completion date: April 15, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Phase 1 stage:

Inclusion criteria:

1. Male subjects aged 18-50 years;

2. In good state of health, determined by medical history, physical exam, and normal laboratory tests at screening;

3. Are able to provide informed consent for participation;

4. Are able and willing to comply with the study schedule and procedures. Exclusion Criteria

1. Active SARS-CoV-2 infection demonstrated by positive polymerase chain reaction (PCR) at enrollment;

2. Requiring CPAP for sleep apnea;

3. Pre-existing pulmonary disease;

4. Have any serious acute concomitant illness that, in the opinion of the investigator, would interfere with evaluation of safety of AP-003, or put the participant at risk of harm from study participation;

5. Are currently receiving an investigational agent, have participated in another study of an investigational agent within 30 days of enrollment, or were previously enrolled in the current study;

6. Are legally incompetent and unable to understand the study's purpose, significance, and consequences, and to make decisions accordingly;

7. Have known hypersensitivity to interferon alpha or any component of the study drug or placebo control. Phase 2 stage:

Inclusion criteria:

1. Active SARS-CoV-2 infection demonstrated by positive polymerase chain reaction (PCR) = 5 days at enrollment;

2. Symptomatic of mild or moderate COVID-19 for = 5 days at enrollment. Symptoms can include fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms, chest pain, with or without shortness of breath on exertion/dyspnea;

3. Age = 18 years;

4. Are able to provide informed consent for participation;

5. Are able and willing to comply with the study schedule and procedures. Exclusion Criteria

1. Patients requiring CPAP for sleep apnea.

2. Patients with pre-existing pulmonary disease requiring chronic O2 supplementation.

3. Patients with known infection with Influenza A or B;

4. In the opinion of the Investigator, should undergo ventilatory (CPAP, mechanical ventilation, etc.) or circulatory support within 24 hours of study enrollment;

5. Have any serious acute concomitant illness that, in the opinion of the Investigator, would interfere with evaluation of safety or efficacy, or put the participant at risk of harm from study participation;

6. Are currently receiving an investigational agent, have participated in another study of an investigational agent within 30 days of enrollment, or were previously enrolled in the current study;

7. Are legally incompetent and unable to understand the study's purpose, significance, and consequences, and to make decisions accordingly;

8. Women who are pregnant or breast-feeding, or planning to conceive in the next 30 days;

9. Have known hypersensitivity to interferon alpha or any component of the study drug or placebo control.

Related Conditions & MeSH terms

• Coronavirus Disease 2019
• Coronavirus Infections
• COVID-19

Intervention

Drug:
• Interferon-Alpha2B
Nebulized interferon alpha 2B
• Placebo
Nebulized placebo

Locations

Country	Name	City	State
Chile	Red de Salud UC Christus	Santiago	RM

Sponsors (2)

Lead Sponsor	Collaborator
Pontificia Universidad Catolica de Chile	Altum Pharmaceuticals INC

Country where clinical trial is conducted

Chile, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Treatment-emergent adverse events in healthy subjects	Safety and tolerability of AP-003 as measured by subject incidence of treatment-emergent adverse events.	At the end of Phase 1 (Phase 1 is 11 days)
Primary	Change in perception of health status measured by EQ VAS in COVID-19 patients	Changes from baseline evaluation in COVID-19(+) participants' perception of health status at Day 5 as measured by EQ VAS in AP-003 treated patients compared to placebo.	At Day 5 of Phase 2 (Phase 2 is 28 days)
Secondary	Serum levels of interferon alpha 2b	Pharmacokinetics of nebulized AP-003 in healthy adults assessed by serial serum quantification of interferon alpha 2b	Up to Day 11 of Phase 1 (Phase 1 is 11 days)
Secondary	Expression of interferon-induced genes in blood sputum samples	Evaluation of interferon-induced biomarkers after treatment with AP-003 in blood and sputum of healthy adults to assess biological effect of Interferon	Up to Day 11 of Phase 1 (Phase 1 is 11 days)
Secondary	Change in perception of health status measured by EQ VAS	Changes in participants' perception of health status from baseline to Day 10 as measured by EQ VAS in AP-003 treated patients compared to placebo.	Day 10 of Phase 2 (Phase 2 is 28 days)
Secondary	Change in perception of health status measured by EQ VAS	Changes in participants' perception of health status from baseline to Day 28 as measured by EQ VAS in AP-003 treated patients compared to placebo.	Day 28 of Phase 2 (Phase 2 is 28 days)
Secondary	Change in EuroQoL Quality of Life instrument (EQ-5D-5L)	Changes in participants' perception of health status from baseline to Day 5, from baseline to Day 10, and from baseline to Day 28 as measured by EuroQoL Quality of Life instrument (EQ-5D-5L).	Up to day 28 of Phase 2 (Phase 2 is 28 days)
Secondary	Change in Ordinal Scale for Clinical Improvement	Changes in participants' overall health from baseline to Day 5, from baseline to Day 10, and from baseline to Day 28 as measured by Ordinal Scale for Clinical Improvement in AP-003 treated patients compared to placebo.	Up to day 28 of Phase 2 (Phase 2 is 28 days)
Secondary	Improvement in clinical symptoms	Changes in participant's improvement in clinical symptoms from baseline to Day 5, from baseline to Day 10, and from baseline to Day 28 as measured by a daily symptom diary in AP-003 treated patients compared to placebo.	Up to day 28 of Phase 2 (Phase 2 is 28 days)
Secondary	Emergency department visits	The proportion of participants attending an emergency department for COVID-19 by Day 28 in AP-003 treated patients compared to placebo.	Up to day 28 of Phase 2 (Phase 2 is 28 days)
Secondary	Hospitalizations	The proportion of participants hospitalized for COVID-19 by Day 28 in AP-003 treated patients compared to placebo.	Up to day 28 of Phase 2 (Phase 2 is 28 days)
Secondary	Duration of hospitalization	For hospitalized participants, duration of hospitalization in AP-003 treated patients compared to placebo.	Up to day 28 of Phase 2 (Phase 2 is 28 days)
Secondary	Time from consent to clinical deterioration	Time from consent to clinical deterioration defined as requiring or recommended for ventilatory support (continuous positive airway pressure [CPAP] or ventilator), shock requiring vasopressor support, and/or heart failure (defined as left ventricular ejection fraction [LVEF] < 30%) in AP-003 treated patients compared to placebo.	Up to day 28 of Phase 2 (Phase 2 is 28 days)
Secondary	Change in SARS CoV-2 viral load	SARS CoV-2 viral load by quantitative PCR from baseline to Day 5, from baseline to Day 10, and from baseline to Day 28 in AP-003 treated patients compared to placebo.	Up to day 28 of Phase 2 (Phase 2 is 28 days)
Secondary	Change in inflammatory parameters	Changes in D dimer, CRP, Ferritin, Troponin, creatine phosphokinase (CPK), LDH, IL-6 from baseline through Day 28 in AP-003 treated patients compared to placebo.	Up to day 28 of Phase 2 (Phase 2 is 28 days)
Secondary	Organ failure rate	Organ failure, any organ, from consent through Day 28 in AP-003 treated patients compared to placebo.	Up to day 28 of Phase 2 (Phase 2 is 28 days)
Secondary	Death rate	Death, any cause, from consent through Day 28 in AP-003 treated patients compared to placebo.	Up to day 28 of Phase 2 (Phase 2 is 28 days)